RT Journal Article
SR Electronic
T1 Role of ivermectin in the prevention of COVID-19 infection among healthcare workers in India: A matched case-control study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.29.20222661
DO 10.1101/2020.10.29.20222661
A1 Priyamadhaba Behera
A1 Binod Kumar Patro
A1 Arvind Kumar Singh
A1 Pradnya Dilip Chandanshive
A1 Ravi Kumar S.R.
A1 Somen Kumar Pradhan
A1 Siva Santosh Kumar Pentapati
A1 Gitanjali Batmanabane
A1 Biswa Mohan Padhy
A1 Shakti Bal
A1 Sudipta Ranjan Singh
A1 Rashmi Ranjan Mohanty
YR 2020
UL http://medrxiv.org/content/early/2020/11/03/2020.10.29.20222661.abstract
AB Background Ivermectin is one among several potential drugs explored for its therapeutic and preventive role in COVID-19 infection. The study was aimed to explore the association between ivermectin prophylaxis and development of COVID-19 infection among healthcare workers.Methods A hospital-based matched case-control study was conducted among healthcare workers of AIIMS Bhubaneswar, India, from September to October 2020. Profession, gender, age and date of diagnosis were matched for 186 case-control pairs. Cases and controls were healthcare workers who tested positive and negative, respectively, for COVID-19 by RT-PCR. Exposure was defined as the intake of ivermectin and/or hydroxychloroquine and/or vitamin-C and/or other prophylaxis for COVID-19. Data collection and entry was done in Epicollect5, and analysis was performed using STATA version 13. Conditional logistic regression models were used to describe the associated factors for COVID-19 infection.Results Ivermectin prophylaxis was taken by 77 controls and 38 cases. Two-dose ivermectin prophylaxis (0.27, 95% CI, 0.15-0.51) was associated with 73% reduction of COVID-19 infection among healthcare workers for the following one month, those who were involved in physical activity (3.06 95% CI, 1.18-7.93) for more than an hour/day were more likely to contract COVID-19 infection. Type of household, COVID duty, single-dose ivermectin prophylaxis, vitamin-C prophylaxis and hydroxychloroquine prophylaxis were not associated with COVID-19 infection.Conclusion Two-dose ivermectin prophylaxis at a dose of 300 μg/kg with a gap of 72 hours was associated 73% reduction of COVID-19 infection among healthcare workers for the following one-month. Further research is required before its large scale use.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was receeived.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the Institutional Ethics Committee of AIIMS, Bhubaneswar via ref number: T/IM-NF/CM&FM/20/125.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the data are available with primary author.